PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
Europe - OSL:PHO - NO0010000045 - Common Stock
50.9 NOK
-0.4 (-0.78%)
Overall PHO gets a fundamental rating of 4 out of 10. We evaluated PHO against 52 industry peers in the Pharmaceuticals industry. PHO has a great financial health rating, but its profitability evaluates not so good. PHO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PHO had negative earnings in the past year.
In the past year PHO had a positive cash flow from operations.
PHO had negative earnings in 4 of the past 5 years.
Of the past 5 years PHO 4 years had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -0.78%, PHO is not doing good in the industry: 64.15% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -1.11%, PHO is doing worse than 64.15% of the companies in the same industry.
PHO's Return On Invested Capital of 0.11% is on the low side compared to the rest of the industry. PHO is outperformed by 67.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| ROIC | 0.11% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 0.17%, PHO is doing worse than 67.92% of the companies in the same industry.
PHO's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 93.40%, PHO belongs to the best of the industry, outperforming 94.34% of the companies in the same industry.
PHO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.17% | ||
| PM (TTM) | N/A | ||
| GM | 93.4% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
PHO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PHO has about the same amount of shares outstanding.
The number of shares outstanding for PHO has been increased compared to 5 years ago.
The debt/assets ratio for PHO has been reduced compared to a year ago.
2.2 Solvency
PHO has an Altman-Z score of 5.27. This indicates that PHO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.27, PHO is in the better half of the industry, outperforming 75.47% of the companies in the same industry.
PHO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.27 |
ROIC/WACC0.01
WACC8.48%
2.3 Liquidity
PHO has a Current Ratio of 4.78. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 4.78, PHO belongs to the best of the industry, outperforming 96.23% of the companies in the same industry.
A Quick Ratio of 4.29 indicates that PHO has no problem at all paying its short term obligations.
The Quick ratio of PHO (4.29) is better than 96.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.29 |
3. Growth
3.1 Past
PHO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -156.82%.
PHO shows a small growth in Revenue. In the last year, the Revenue has grown by 1.81%.
PHO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.29% yearly.
EPS 1Y (TTM)-156.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)1.81%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%9.54%
3.2 Future
The Earnings Per Share is expected to grow by 169.19% on average over the next years. This is a very strong growth
Based on estimates for the next years, PHO will show a quite strong growth in Revenue. The Revenue will grow by 14.98% on average per year.
EPS Next Y490.91%
EPS Next 2Y163.75%
EPS Next 3Y169.19%
EPS Next 5YN/A
Revenue Next Year11.79%
Revenue Next 2Y9.78%
Revenue Next 3Y11.79%
Revenue Next 5Y14.98%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PHO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 57.05, the valuation of PHO can be described as expensive.
Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than the industry average as 71.70% of the companies are valued more cheaply.
When comparing the Price/Forward Earnings ratio of PHO to the average of the S&P500 Index (22.99), we can say PHO is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 57.05 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHO is valued a bit more expensive than 73.58% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 60.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.72 | ||
| EV/EBITDA | 37.96 |
4.3 Compensation for Growth
PHO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHO's earnings are expected to grow with 169.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y163.75%
EPS Next 3Y169.19%
5. Dividend
5.1 Amount
No dividends for PHO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (10/24/2025, 7:00:00 PM)
50.9
-0.4 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.64%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.38B
Revenue(TTM)522.86M
Net Income(TTM)-5330000
Analysts80
Price Target81.09 (59.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)138.57%
Min EPS beat(2)15.13%
Max EPS beat(2)262.02%
EPS beat(4)3
Avg EPS beat(4)30.25%
Min EPS beat(4)-203.96%
Max EPS beat(4)262.02%
EPS beat(8)5
Avg EPS beat(8)48.5%
EPS beat(12)7
Avg EPS beat(12)20.94%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)2.07%
Revenue beat(8)3
Avg Revenue beat(8)-3.45%
Revenue beat(12)6
Avg Revenue beat(12)-2.68%
Revenue beat(16)7
Avg Revenue beat(16)-4.3%
PT rev (1m)0%
PT rev (3m)2.58%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-50.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.28%
Revenue NY rev (1m)1.94%
Revenue NY rev (3m)0.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 57.05 | ||
| P/S | 2.64 | ||
| P/FCF | 39.72 | ||
| P/OCF | 29.97 | ||
| P/B | 2.88 | ||
| P/tB | 5.56 | ||
| EV/EBITDA | 37.96 |
EPS(TTM)-0.25
EYN/A
EPS(NY)0.89
Fwd EY1.75%
FCF(TTM)1.28
FCFY2.52%
OCF(TTM)1.7
OCFY3.34%
SpS19.28
BVpS17.69
TBVpS9.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| ROCE | 0.14% | ||
| ROIC | 0.11% | ||
| ROICexc | 0.18% | ||
| ROICexgc | 0.49% | ||
| OM | 0.17% | ||
| PM (TTM) | N/A | ||
| GM | 93.4% | ||
| FCFM | 6.65% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score4
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.76% | ||
| Cap/Sales | 2.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.29 | ||
| Altman-Z | 5.27 |
F-Score4
WACC8.48%
ROIC/WACC0.01
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-156.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y490.91%
EPS Next 2Y163.75%
EPS Next 3Y169.19%
EPS Next 5YN/A
Revenue 1Y (TTM)1.81%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%9.54%
Revenue Next Year11.79%
Revenue Next 2Y9.78%
Revenue Next 3Y11.79%
Revenue Next 5Y14.98%
EBIT growth 1Y-97.81%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year125.85%
EBIT Next 3Y71.38%
EBIT Next 5YN/A
FCF growth 1Y-3.32%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y9.51%
OCF growth 3Y47.56%
OCF growth 5Y30.02%
PHOTOCURE ASA / PHO.OL FAQ
What is the fundamental rating for PHO stock?
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL.
Can you provide the valuation status for PHOTOCURE ASA?
ChartMill assigns a valuation rating of 2 / 10 to PHOTOCURE ASA (PHO.OL). This can be considered as Overvalued.
Can you provide the profitability details for PHOTOCURE ASA?
PHOTOCURE ASA (PHO.OL) has a profitability rating of 2 / 10.
How financially healthy is PHOTOCURE ASA?
The financial health rating of PHOTOCURE ASA (PHO.OL) is 8 / 10.